ORBIMED ADVISORS LLC

Q2 2021 13F-HR Holdings

Location
New York, NY
Holdings as of
6/30/2021
Date filed
8/16/2021
Form type
13F-HR
Num holdings
159
Total value ($000)
$9,886,767
Net value change ($000)
-808,159 (-7.6%)
New positions
22
Sold out positions
20
Turnover %
10.4%
Sector allocation + QoQ delta (equities-only)

Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown

Prev filing: 5/17/2021 Next filing: 11/15/2021 SEC filing

Snapshot: Change Analysis

Compared to Q1 2021
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
XBI 126,694 NEW
NPCE 95,452 NEW
JANX 86,486 NEW
VectivBio Holding AG 59,738 NEW
Deciphera Pharmaceuticals, Inc. 58,794 95.0%
Singular Genomics Systems, Inc. 54,919 NEW
SEM 53,717 NEW
SpringWorks Therapeutics, Inc. 42,981 9.4%
LENZ 33,997 NEW
GHRS 31,045 NEW
Top Reduces (Value $000, Stocks/ETFs)
EWTX -155,762 -34.4%
PRLD -147,584 -33.9%
ABCL -141,592 -50.8%
SPRY -111,359 -29.2%
HAE -94,581 -100.0%
TBPH -60,662 -47.8%
ADVM -54,241 -100.0%
XTNT -53,197 -30.9%
IMA -41,691 -50.3%
IRON -41,249 -52.3%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 24,135 (0.2% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type